Skip to main content

Table 2 The prevalence of HPV-16 antibodies in CIN patients (Pt) according to their grade of CIN (CIN0, CIN1 or CIN2/3) and HPV-16 infection at the cervix.

From: More men than women make mucosal IgA antibodies to Human papillomavirus type 16 (HPV-16) and HPV-18: a study of oral HPV and oral HPV antibodies in a normal healthy population

  Pt HPV types HPV-16 IgA HPV-16 IgG
  no cervical Oral serum oral serum
CIN 0 88 11, 16, 18, 35, 42, 55     
  79 16, 18, 31, 35, 55, 58  
  87 16, 51, 55    
CIN 1 92 16   
  85 16, 58, 61  
CIN 2/3 74 16     
  80 16     
  86 16    
  93 16     
  95 16    
  122 16  
  123 16, 45, 70, 61   
  108 16, 45, 70, CP6108    
  109 16, 51, IS39, 83   
  121 16, 68   
  99 16, 39   
  100 16, 52, 66   
Number 17   9 6 5 5
%    52.9 35.3 29.4 29.4
CIN 0 103 35  
  111 53   
  112 58   
  90 33, 61  
  75 42, 51, 56    
  104 51, 56    
  107 negative   
  110 negative  
  120 negative   
CIN 1 119 45   
  101 51
  106 53   
  84 56   
  78 35, 59     
  89 35, 62     
  91 51, 53, 54, 59, 68  
  116 52, 33, 35, 58
  115 58, 66   
  76 negative   
  114 negative   
CIN 2/3 117 35    
  105 18, 6    
  113 31, 45   
  94 31, 58   
  118 33, 45, 58, 66  
  82 45, 82   
  81 51, 58  
Number 27   21 16 9 10
%    77.8 59.3 33.3 37.0
total 44   68.2 50.0 31.8 34.1
  1. Empty cells indicate a negative antibody result
  2. Black boxes indicate a positive antibody result